Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
DAIC
MAY 6, 2024
Initially discovered and developed by Orion Corporation in Finland, intravenous levosimendan is approved in 60 countries outside the United States for use in hospitalized patients with acutely decompensated heart failure. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,
Let's personalize your content